Clinical Trial Update: FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT [NA]

View source ↗

Summary

Clinical trial update for the FAME II study comparing FFR-guided PCI plus optimal medical therapy to optimal medical therapy alone in coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PCI (percutaneous coronary intervention) with fractional flow reserve guidance (fractional flow reserve-guided PCI)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Artery Disease | NA | Status: COMPLETED | Results posted: 2016-12-09